Quantum BioPharma Receives Health Canada License for Qlarity Natural Health Product
TL;DR
Quantum BioPharma gains a competitive edge with Health Canada's Qlarity license, expanding market reach and potential revenue from Canadian sales.
Health Canada granted Quantum BioPharma a product license for Qlarity, permitting its sale with specified uses based on regulatory approval processes.
Qlarity's approval supports public health by aiding energy, cognition, and fatigue reduction, contributing to improved daily wellness in Canada.
Quantum BioPharma's Qlarity, now licensed in Canada, offers a natural boost for mental alertness and endurance, building on its U.S. counterpart unbuzzd.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received a Product License from Health Canada for its natural health product Qlarity, marking a significant regulatory milestone for the biopharmaceutical company. The license, numbered PN 80144141, authorizes the sale of Qlarity in Canada with recommended uses including support for energy production, metabolism, electrolyte balance, mental alertness, cognitive performance, endurance, and fatigue reduction.
This approval represents Quantum BioPharma's expansion into the Canadian market, building on its previous success with a similar product licensed in the United States under the brand name unbuzzd(TM). The company's ability to secure regulatory approvals in multiple countries demonstrates its growing presence in the natural health product sector and its commitment to developing scientifically-backed formulations.
The licensing achievement is particularly important given Quantum BioPharma's broader focus on neurodegenerative and metabolic disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is developing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, making this research potentially significant for patients suffering from this challenging condition.
Quantum BioPharma's business strategy includes maintaining ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, with royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, providing flexibility for future product development.
For more information about Quantum BioPharma's developments, investors can access the company's newsroom at https://ibn.fm/QNTM. The Health Canada approval of Qlarity represents not only a revenue opportunity for Quantum BioPharma but also expands consumer access to scientifically-formulated natural health products in the Canadian market.
Curated from InvestorBrandNetwork (IBN)
